BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 18084154)

  • 1. Temsirolimus (Torisel) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
    [No Abstract]   [Full Text] [Related]  

  • 2. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ; Hsu A
    Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
    Jafri M; Douis H; Porfiri E
    Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):657-8. PubMed ID: 18644704
    [No Abstract]   [Full Text] [Related]  

  • 6. Temsirolimus for advanced renal cell carcinoma.
    Figlin RA
    Clin Adv Hematol Oncol; 2007 Nov; 5(11):893. PubMed ID: 18185488
    [No Abstract]   [Full Text] [Related]  

  • 7. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.
    Gerullis H; Bergmann L; Maute L; Eimer C; Otto T
    Cancer Chemother Pharmacol; 2009 May; 63(6):1097-102. PubMed ID: 18818922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temsirolimus in patients with advanced renal cell carcinoma: an overview.
    Bhatia S; Thompson JA
    Adv Ther; 2009 Jan; 26(1):55-67. PubMed ID: 19172239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T; Mis L; Hammond JM
    Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.
    Paterson C; Jones RJ
    Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):732-3. PubMed ID: 19665360
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma.
    Rodríguez Faba O; Breda A; Rosales A; Palou J; Algaba F; Maroto Rey P; Villavicencio H
    Eur Urol; 2010 Aug; 58(2):307-10. PubMed ID: 20347211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecule of the month. Temsirolimus.
    Drug News Perspect; 2007; 20(6):406. PubMed ID: 17925894
    [No Abstract]   [Full Text] [Related]  

  • 14. [ASCO 2006: temsirolimus increases survival].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):12. PubMed ID: 23646393
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
    Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
    Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
    De Masson A; Fouchard N; Méry-Bossard L; Dauendorffer JN
    Dermatology; 2011; 223(1):4-8. PubMed ID: 21846963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.
    Boni JP; Hug B; Leister C; Sonnichsen D
    Semin Oncol; 2009 Dec; 36 Suppl 3():S18-25. PubMed ID: 19963096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of mTOR inhibitor side effects.
    Creel PA
    Clin J Oncol Nurs; 2009 Dec; 13 Suppl():19-23. PubMed ID: 19948456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temsirolimus in renal cell carcinoma.
    Otto T; Eimer C; Gerullis H
    Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temsirolimus for advanced renal cell carcinoma.
    Bergmann L; Maute L; Guschmann M
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.